Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies

Figure 3

The CDR3 length of the TCRB repertoire in bDMARD-treated RA patients. (a) The distributions of the CDR3 amino acid lengths of the TCRB clonotypes in RA patients receiving adalimumab only (A1 and A2), adalimumab followed by rituximab (R1, R2, and R3), and adalimumab followed by tocilizumab (T1, T2, and T3) are illustrated. (b) The intragroup repertoire dissimilarity index (RDI) values of TCRB CDR3 lengths between each pair of RA patients are represented.

(a)

(b)